Erste Asset Management GmbH Buys 44,067 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Erste Asset Management GmbH increased its stake in Bristol Myers Squibb (BMY) by 27.2%, owning 206,277 shares worth approximately $12.29 million as of its latest SEC filing.
• Institutional investors now hold 76.41% of Bristol Myers Squibb's shares, reflecting significant interest in the biopharmaceutical company.
• Bristol Myers Squibb reported a quarterly earnings per share (EPS) of $1.46, exceeding estimates and reflecting a revenue of $12.27 billion for the quarter, which was up 0.6% from the previous year.

Erste Asset Management GmbH raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 27.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 206,277 shares of the biopharmaceutical company's stock after purchasing an additional 44,067 shares during the period. Erste Asset Management GmbH's holdings in Bristol Myers Squibb were worth $12,292,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of Bristol Myers Squibb by 0.8% during the first quarter. Vanguard Group Inc. now owns 191,403,004 shares of the biopharmaceutical company's stock valued at $11,673,669,000 after purchasing an additional 1,458,488 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Bristol Myers Squibb by 0.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 60,606,905 shares of the biopharmaceutical company's stock valued at $3,696,415,000 after purchasing an additional 306,430 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Bristol Myers Squibb by 59.9% during the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after acquiring an additional 12,011,983 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Bristol Myers Squibb by 8.6% during the first quarter. Bank of New York Mellon Corp now owns 26,865,073 shares of the biopharmaceutical company's stock valued at $1,638,501,000 after acquiring an additional 2,131,205 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Bristol Myers Squibb by 5.3% during the first quarter. Northern Trust Corp now owns 25,974,504 shares of the biopharmaceutical company's stock valued at $1,584,185,000 after acquiring an additional 1,316,144 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock traded down $0.5880 on Friday, hitting $47.8420. 11,602,099 shares of the company's stock were exchanged, compared to its average volume of 12,653,990. The company has a 50-day simple moving average of $47.06 and a 200-day simple moving average of $51.06. The stock has a market capitalization of $97.38 billion, a PE ratio of 19.29, a PEG ratio of 2.45 and a beta of 0.36. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to analysts' expectations of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company's revenue was up .6% compared to the same quarter last year. During the same quarter last year, the company posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.2%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on BMY shares. Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Citigroup reduced their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research report on Friday, August 1st. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Finally, Daiwa Capital Markets cut shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price on the stock. in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $56.38.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.